Generalized Pustular Psoriasis: Provider and Payer Considerations for Care

Mark G. Lebwohl, MD, gives an overview of generalized pustular psoriasis (GPP) and explains how it differs from the more common plaque psoriasis.

Mark G. Lebwohl, MD, explains what causes generalized pustular psoriasis (GPP) and the potential triggers for GPP episodes.

Mark G. Lebwohl, MD, discusses how IL-36 mutations can play a part in disease presentation and how IL-17 and IL-23 pathways are more often implicated in plaque psoriasis.

Aaron Farberg, MD, and Maria Lopes, MD, MS, discuss what makes generalized pustular psoriasis a potentially life-threatening condition and where patients with the disease typically present and receive treatment.

Mark G. Lebwohl, MD, and Maria Lopes, MD, MS, review the incidence and prevalence of generalized pustular psoriasis as well as direct and indirect costs associated with the disease.

Aaron Farberg, MD, and Mark G. Lebwohl, MD, discuss the relapsing nature of generalized pustular psoriasis and how the difficulty in diagnosing the disease affects outcomes for patients.

Aaron Farberg, MD, and Mark G. Lebwohl, MD, review the biggest unmet needs of patients with generalized pustular psoriasis (GPP) and the impact GPP has on their quality of life.

Maria Lopes, MD, MS, and Mark G. Lebwohl, MD, discuss how the impact that generalized pustular psoriasis (GPP) has on quality of life can be reduced and how the effects are measured in practice.

Aaron Farberg, MD, and Mark G. Lebwohl, MD, discuss the common comorbidities seen in patients with generalized pustular psoriasis (GPP) and some potential future developments in the management of GPP.

Aaron Farberg, MD, reviews medications that are approved to treat generalized pustular psoriasis and the potential role of combination therapy.

Mark G. Lebwohl, MD, explores the role of topical treatments such as corticosteroids and tacrolimus in treating generalized pustular psoriasis (GPP) and important safety considerations.

Maria Lopes, MD, MS, explains how the setting of care for spesolimab may impact coverage policies and access to the medication.

Maria Lopes, MD, MS, reviews how clinicians and payers can work together to minimize any potential treatment delays, ensuring patients receive needed care in the timeliest manner.

Aaron Farberg, MD, and Mark G. Lebwohl, MD, explore the typical hospital length of stay for patients with an acute generalized pustular psoriasis (GPP) flare, and define treatment success with GPP therapies.

A panel of experts provide their final thoughts on generalized pustular psoriasis, the treatment for this disease, and the impact it has on patients.